MedTrace Logo

A Clinical Study to Determine the Safety and Efficacy of an Oral Supplementation of Bio-Immune®for Managing Upper Respiratory Tract Infection and Its Symptoms.

NCT06689995 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-02-28

No results posted yet for this study

Summary

This is a prospective, interventional, randomised, double-blind, placebo-controlled, proof-of-science, in-use safety and efficacy study of an oral supplementation of Bio-Immune® for managing upper respiratory tract infection and its symptoms.

Conditions

Interventions

OTHER

Bio-immune Capsule

Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days Dose: 100 mg

OTHER

Placebo

Dosage Form: Capsule Route of administration: Oral Frequency: 1 capsule, twice a day after meal for 5 days

Sponsors & Collaborators

  • Ambe Phytoextracts Pvt. Ltd

    collaborator INDUSTRY

  • NovoBliss Research Pvt Ltd

    lead OTHER

Principal Investigators

  • Dr. Nayan K Patel · NovoBliss Research Pvt Ltd

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2025-01-29
Completion
2025-01-29

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06689995 on ClinicalTrials.gov